600 patients66,869 observations120 daysLIVE

Patient P-01336

Synthetic patientNBL-101 · Day 111 · 75+ · F · baseline S03Open companion preview
Therapy response
Improving
Tolerance
Stable
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Improving
Discontinuation risk
54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S03
  2. Day 45 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 50 GI-04 recommendedGI Support Protocol GI-04
  4. Day 51 Patient acceptedStarted GI-04 in the companion
  5. Day 59 GI symptom burden −35% vs expectedGI Support Protocol GI-04
  6. Day 65 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days
  • GI instability-10
  • Nutritional resilience+6
  • Treatment adherence-2

What helped?

  • GI Support Protocol GI-04Day 50
    Result: symptom burden −35%
LIFE OS recommendation
Dietary Support Protocol NP-02
57%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 54
    • WearableHRV 17 ms, trending down
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 32/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 40
  • Mucosal barrier integrity 20
    • Daily logGI symptom score 50 and rising
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 2.3 · butyrate capacity 32/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
18 ms
Sleep
6.7 h
Steps
6,340
Resting HR
71 bpm
Daily log: GI score 50, nutritional resilience 45, adherence 48.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0166160%S03GI-04improved52
P-0187955%S14SC-12improved51
P-0162453%S14GI-04improved52
P-0140052%S17GI-04improved51
P-0170652%S14GI-04improved55
P-0142951%S09GI-04improved45
P-0139349%S14GI-04improved53
P-0161149%S14GI-04improved44
P-0162749%S14GI-04improved54
P-0146248%S14NP-02improved47
P-0155648%S14GI-04improved44
P-0157348%S14GI-04improved49